Responses
Other responses
Jump to comment:
- Published on: 14 November 2005
- Published on: 22 August 2005
- Published on: 20 July 2005
- Published on: 14 November 2005Gaviscon Infant® is effective symptomatically in infant reflux-associated symptomsShow More
Dear Editor
In response to the comments of Paisal (1), regarding our study on the influence of Gaviscon Infant® on gastro-oesophageal reflux in infants studied by the new physiologically appropriate modality of combined intraluminal oesophageal pH/impedance (2), we would like to make the following points.
Commenting on the study design he points to two studies which found benefit of Gaviscon. What he...
Conflict of Interest:
None declared. - Published on: 22 August 2005Gaviscon on gastro-oesophageal reflux in infants: A poorly effective treatment?Show More
Dear Editor,
We read with interest the recent article by Del Buono et al. evaluating the effect of sodium and magnesium alginate (Gaviscon) on gastro-oesophageal reflux (GER) in infants [1]. It provides an objective assessment of the effects of a drug widely used in the treatment of paediatric GER by means of a double-blind drug vs placebo trial, in which the effects of each treatment were evaluated by means of...
Conflict of Interest:
None declared. - Published on: 20 July 2005Absence of wash-out period between Gaviscon and placebo may be responsible for anomalous findingsShow More
Dear Editor,
Oesophageal pH monitoring has been used to monitor gastro-oesophageal reflux (GOR). However, Buono et al. point out that this method will not record instances of 'neutral-reflux' after a feed (1). They say that multiple intraluminal impedance measurement is a more appropriate way to assess GOR. Using the technique they have found that Gaviscon does not reduce reflux. The number and height of reflux with Gav...
Conflict of Interest:
None declared.